ChemoCentryx

SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place…

-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose…

SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in…

As a small cap biotech, it doesn’t get much more risky than ChemoCentryx, Inc. (NASDAQ: CCXI). Not many companies see their share price soar from $10 to $70 only to plunge back…

-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits…

SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for…

-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time -- SAN CARLOS, Calif., Oct. 08, 2021…

SAN CARLOS, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese…